NICE recommends Revolade (GSK) for ITP

The National Institute for Health and Clinical Excellence(NICE) now recommends the use of Revolade (eltrombopag olamine)for patients with the bleeding disorder Chronic Immune Thrombocytopenic Purpura (ITP). The recommendation is for use of the drug for treating ITP in patients who have had their spleens removed or those refractory to other treatments, or as a second line treatment in those who have not undergone a splenectomy because surgery is contraindicated.